Ivan Hyep's most recent trade in Bicara Therapeutics Inc. was a trade of 22,757 Common Stock done at an average price of $28.6 . Disclosure was reported to the exchange on July 8, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.60 per share. | 08 Jul 2026 | 22,757 | 135,098 | - | 28.6 | 650,896 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 08 Jul 2026 | 12,500 | 157,855 | - | 3.8 | 47,373 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2026 | 11,592 | 58,992 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 29.82 per share. | 08 Jul 2026 | 4,413 | 130,685 | - | 29.8 | 131,616 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2026 | 908 | 38,836 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.31 per share. | 08 Jul 2026 | 830 | 129,855 | - | 30.3 | 25,160 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 21 May 2026 | 9,200 | 154,555 | - | 3.8 | 34,866 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2026 | 9,200 | 70,584 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.42 per share. | 21 May 2026 | 9,200 | 145,355 | - | 20.4 | 187,883 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 23.00 per share. | 21 Apr 2026 | 9,200 | 145,355 | - | 23.0 | 211,614 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2026 | 9,200 | 39,744 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 21 Apr 2026 | 9,200 | 154,555 | - | 3.8 | 34,866 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 23 Mar 2026 | 9,200 | 154,555 | - | 3.8 | 34,866 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.52 per share. | 23 Mar 2026 | 9,200 | 145,355 | - | 18.5 | 170,348 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Mar 2026 | 9,200 | 48,944 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.22 per share. | 03 Mar 2026 | 13,555 | 145,355 | - | 18.2 | 246,910 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 03 Mar 2026 | 7,318 | 152,673 | - | 3.8 | 27,734 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 7,318 | 58,144 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 03 Mar 2026 | 6,237 | 158,910 | - | 3.8 | 23,637 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 6,237 | 82,747 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.25 per share. | 03 Mar 2026 | 2,963 | 145,355 | - | 18.2 | 54,062 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 03 Mar 2026 | 2,963 | 148,318 | - | 3.8 | 11,229 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 2,963 | 79,784 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 22 Jan 2026 | 1,882 | 147,237 | - | 3.8 | 7,132 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.15 per share. | 22 Jan 2026 | 1,882 | 145,355 | - | 18.2 | 34,162 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2026 | 1,882 | 65,462 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2025 | 9,200 | 88,984 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.31 per share. | 22 Dec 2025 | 9,200 | 145,355 | - | 18.3 | 168,492 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 22 Dec 2025 | 9,200 | 154,555 | - | 3.8 | 34,866 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 21 Nov 2025 | 17,795 | 163,150 | - | 3.8 | 67,439 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 17,795 | 98,184 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.55 per share. | 21 Nov 2025 | 17,795 | 145,355 | - | 18.5 | 330,094 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 605 | 115,979 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.15 per share. | 21 Nov 2025 | 605 | 145,355 | - | 18.2 | 10,981 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 21 Nov 2025 | 605 | 145,960 | - | 3.8 | 2,293 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 09 Oct 2025 | 6,415 | 151,770 | - | 3.8 | 24,312 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Oct 2025 | 6,415 | 116,584 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.23 per share. | 09 Oct 2025 | 6,415 | 145,355 | - | 18.2 | 116,931 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 18,244 | 128,626 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.22 per share. | 06 Oct 2025 | 18,244 | 145,355 | - | 18.2 | 332,386 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 06 Oct 2025 | 18,244 | 163,599 | - | 3.8 | 69,141 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.17 per share. | 06 Oct 2025 | 6,514 | 145,355 | - | 18.2 | 118,356 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 06 Oct 2025 | 6,514 | 151,869 | - | 3.8 | 24,687 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 6,514 | 146,870 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 5,627 | 122,999 | - | - | Stock Option (Right to Buy) | |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.21 per share. | 06 Oct 2025 | 5,627 | 145,355 | - | 18.2 | 102,456 | Common Stock |
| Bicara Therapeutics Inc | Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 06 Oct 2025 | 5,627 | 150,982 | - | 3.8 | 21,325 | Common Stock |